openPR Logo
Press release

Reduced Drug Development Costs Steer Pharmaceutical Companies to Develop Companion Diagnostics

07-13-2016 09:20 AM CET | Health & Medicine

Press release from: TMR

Pharmaceutical companies are bearing high costs involved with the development and commercialization of drugs and drug discoveries. Thus, there has been an increased focus by pharmaceutical companies on regulating the costs incurred by means of developing companion diagnostics along with therapeutic drugs. The strategy of co-development allows for the commercial availability of safe and effective drugs and thus, companion diagnostics are expected to materialize as efficient diagnostic tools that will be advantageous for pharmaceutical manufacturers.

Of late, there has been an increased demand for personalized medicines, which in turn is driving the demand for companion diagnostics, states a research report by Transparency Market Research (TMR). According to the report, the market for companion diagnostics is expected to expand at an 18.1% CAGR from 2013 to 2019.

TMR analysts answer key questions that companies operating in the companion diagnostic market need to ask:

Q. How are companion diagnostics revolutionizing patient care?

Companion diagnostics help eliminate the possibility of side effects by identifying the patients who are most likely to be at risk of several side effects by the use of a particular therapeutic drug. They identify the patients who are most likely to benefit from a particular therapeutic drug and monitor the response of the patient to a treatment with a particular therapeutic drug.

Monitoring patients’ response to a medicine is done to enable adjustments in the treatment, for improved effectiveness and safety. For instance, the cobas 4800 BRAF V600 mutation test, which is a companion diagnostic for vemurafenib, helps in the detection of the BRAF V600E mutation in the DNA extracted from human melanoma tissue. Developed by Roche Holdings AG, a Switzerland-based biotech company, the test is intended to be used on selected melanoma patients whose tumors carry the BRAF V600R mutation.

Q. What are the factors challenging the growth of the companion diagnostics market?

The global companion diagnostics market is hampered to a great extent by prolonged developmental and approval period. The need to have both the drug and the device ready to be launched in the market at the same time, can potentially delay approvals. The delays in approvals of personalized medicines deprive the patients of these medicines for prolonged periods, thus hampering the uptake and sales of companion diagnostics.

Clinical societies have a huge influence on the acceptance of companion diagnostics by end users. The views and opinions of these societies can affect the market as they impart education by giving biased opinions on their own experience with companion diagnostics. These clinical societies pose as key opinion holders and can alter the preference for companion diagnostics among patients.

Get Free Sample Research Report: 
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=387

Q. What is the progress in the field of companion diagnostics?

Companion diagnostics have been highly successful in the oncology area. This success is encouraging the development of companion diagnostics for other indications such as metabolism disorders, central nervous system (CNS) disorders, and infectious diseases. There have been discoveries of biomarkers for newer indication areas, which is expected to lead to a high growth and increase the revenue generation of the companion diagnostics market.

Case in point, Exosome Diagnostics, Inc. has entered into a collaboration with Takeda Pharmaceuticals International Co. to develop an exosomal RNA sequencing platform for biomarkers. With a goal to develop a platform for serial analysis of gene expression patterns beyond oncology, the analysis of RNAs will provide an innovative tool for patient characterization to select patients. It will then monitor the disease and track the response to the therapeutic drug over the time of the treatment in the patient. This biomarker platform is expected to be an effective therapy for patients not just with cancer but with CNS disorders.

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

90 State Street, Suite 700 Albany, NY 12207

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Reduced Drug Development Costs Steer Pharmaceutical Companies to Develop Companion Diagnostics here

News-ID: 348587 • Views:

More Releases from TMR

Emerging Opportunities in Logistics Market with Current Trends Analysis
Emerging Opportunities in Logistics Market with Current Trends Analysis
The global Logistics market is estimated to attain a valuation of US$ 15,273.21 Bn by the end of 2027, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 4.5% during the forecast period, 2019-2027. The key objective of the TMR report is to offer a complete assessment of the global market including major leading stakeholders of the
Energy Measurement IC Market is expected to reach US$ 8.39 Bn by the end of 2031
According to a Transparency Market Research (TMR) research report, the global energy measurement ic market is likely to expand at a CAGR of 7.4% during the forecast period, 2022 to 2031. This suggests that the market is expected to reach US$ 8.39 Bn by the end of 2031. The study on the energy measurement ic market adopts rigorous and systematic research approaches to understand the growth dynamic of the market. The
STATCOM UPS Market to Register Double Digit Growth Rate of 16% CAGR by 2024
Over the last decade, rising number of industries and utilities are opting for static synchronous compensator or STATCOM UPS instead of static VAR compensator or SVC UPS. Low harmonic emission coupled with high speed of response is accentuating the expansion of India STATCOM UPS market now and in times to come. Playing a crucial role in voltage control and compensation of reactive power, STATCOM UPS is likely to keep its
Thin Wafer Processing and Dicing Equipment Market US$692.5 mn by 2024 - TMR
Transparency Market Research (TMR) estimates that the global thin wafer processing and dicing equipment market has a highly consolidative landscape. Disco Corp. accounted for largest share of 56.4% in 2015 and likely to be dominant in the coming years. This is creating monopoly in the thin wafer processing and dicing equipment market in terms of competitive presence. The other key players such as EV Group, Plasma-Therm LLC, Lam Research Corp,

All 5 Releases


More Releases for BRAF

BRAF Metastatic NSCLC Market to Reach USD 2.56 Billion by 2034
The B-Rapidly Accelerated Fibrosarcoma (BRAF) mutation-positive metastatic non-small cell lung cancer (NSCLC) market is emerging as a critical segment within the oncology therapeutics landscape. NSCLC accounts for nearly 85% of all lung cancer cases globally, and while BRAF mutations occur in only 1-3% of patients, they represent a unique subset with distinct biological and clinical features. Over the next decade, the market is poised for robust growth as targeted therapies,
BRAF-mutant Non-Small Cell Lung Cancer Pipeline: 10+ Companies Advancing Targete …
The treatment landscape for BRAF-mutant Non-Small Cell Lung Cancer (BRAF+ NSCLC), a molecular subtype of NSCLC driven by mutations in the BRAF gene, most commonly the V600E mutation, is rapidly evolving. Traditionally associated with poor prognosis, BRAF+ NSCLC has witnessed significant clinical progress with the development of targeted therapies that inhibit aberrant MAPK pathway signaling. With growing recognition of the heterogeneity and aggressiveness of BRAF-driven tumors, biopharmaceutical companies are increasingly
BRAF Kinase Inhibitors Market Size Opportunities and Challenges for the Future
The global BRAF Kinase Inhibitors Market was valued at approximately USD 289 million and is projected to reach around USD 618 million by 2032, growing at a compound annual growth rate (CAGR) of 8.8% from 2024 to 2032 . BRAF Kinase Inhibitors Market Overview The BRAF Kinase Inhibitors Market is experiencing significant growth, driven by the increasing prevalence of cancers associated with BRAF mutations, such as melanoma, colorectal cancer, and non-small cell
BRAF Kinase Inhibitors Market to see Huge Growth by 2029
BRAF Kinase Inhibitors Market is anticipated to grow at a significant CAGR during the forecast period. BRAF is a kinase enzyme that helps control cell growth and signalling. This enzyme can be found in a mutated form in some types of cancer, including melanoma and colorectal cancer. Blocking mutated BRAF kinase proteins helps to stop the cancer cells from growing. Some BRAF kinase inhibitors are used to treat cancer. The
BRAF Kinase Inhibitors Market Growth, Challenges, Opportunities and Emerging Tre …
Los Angeles, United States December 2022,- The research study presented here is a brilliant compilation of different types of analysis of critical aspects of the global BRAF Kinase Inhibitors market. It sheds light on how the global BRAF Kinase Inhibitors market is expected to grow during the course of the forecast period. With SWOT analysis and Porter's Five Forces analysis, it gives a deep explanation of the strengths and weaknesses of
Global BRAF Kinase Inhibitors Market Size, Share and Forecast 2021-2027
The global BRAF kinase inhibitors market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). BRAF is a kinase enzyme that helps control cell growth and signalling. This enzyme can be found in a mutated form in some types of cancer, including melanoma and colorectal cancer. Blocking mutated BRAF kinase proteins helps to stop the cancer cells from growing. Some BRAF kinase inhibitors are used to